Company Description
Vitro Biopharma is an innovative biotechnology company targeting autoimmune diseases and inflammatory disorders.
Through our proprietary platform, AlloRx Stem Cell therapy, we are developing novel cellular therapeutic candidates that are derived from culture-expanded mesenchymal stem cells (“MSCs”) sourced from the Wharton’s jelly of umbilical cords (“UCs”) donated by healthy volunteers following childbirth.
In the United States, we are authorized to conduct two clinical trials under two U.S. Food and Drug Administration Investigational New Drug applications to assess the safety and efficacy of AlloRx Stem Cell therapy in Pitt Hopkins syndrome (“PTHS”) and post-acute sequelae to SARs-CoV-2 (“PASC”), or long COVID, and expect to commence those trials in late 2022 or early 2023 following completion of this offering.
To date, over 300 subjects have received treatment with our AlloRx Stem Cells, primarily in foreign clinical studies conducted by third parties.
Our lead clinical program is expected to focus on PTHS, a rare neurogenetic disorder primarily affecting children that is characterized by global developmental delays including autistic features, language delays, intellectual disability, neuro-irritability and significant behavioral concerns.
We generate revenue from our other technologies through a number of other activities, including providing research services and through the sale of our stem cell products as well as cosmeceuticals through InfiniVive MD, our wholly-owned subsidiary, which helps to alleviate our capital expenses.
| Country | United States |
| Founded | 1986 |
| Industry | Health Care |
| Sector | Biotechnology |
| Employees | 12 |
| CEO | Christopher Furman |
Contact Details
Address: 3200 Cherry Creek Drive South, Suite 720 Denver, CO 80209 United States | |
| Phone | (855) 848-7627 |
| Website | vitrobiopharma.com |
Stock Details
| Ticker Symbol | VTRO |
| Exchange | NYSEAMERICAN |
| Fiscal Year | November - October |
| Reporting Currency | USD |
| CIK Code | 0000793171 |
| Employer ID | 84-1012042 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Christopher Furman | Chief Executive Officer, Director |
| Nathan Haas | Chief Financial Officer |
| James R. Musick | Chief Science Officer, Director |
| Caroline Mosessian | Chief Regulatory Officer, Chair of the Board |
| Tiana States | Chief Manufacturing Officer |
| Jack Zamora | Director |
| John Packs | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 12, 2025 | 10-Q | Quarterly Report |
| Jun 20, 2025 | 10-Q | Quarterly Report |
| Jun 16, 2025 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Jun 11, 2025 | D | Notice of Exempt Offering of Securities |
| Mar 20, 2025 | 10-Q | Quarterly Report |
| Mar 17, 2025 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Jan 28, 2025 | 10-K | Annual Report |
| Sep 16, 2024 | 10-Q | Quarterly Report |
| Sep 11, 2024 | EFFECT | Notice of Effectiveness |
| Sep 5, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |